|
26 Sep 2023 |
Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist, in Chronic Inducible Urticaria
|
|
26 Sep 2023 |
Longhorn Vaccines and Diagnostics Presents Data Demonstrating Neutralizing Activity of LHNVD-201 for Covid-19 and Influenza Co-Infections
|
|
25 Sep 2023 |
Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
|
|
25 Sep 2023 |
Novartis radioligand therapy Lutathera® demonstrated statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
|
|
23 Sep 2023 |
Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ESCC
|
|
22 Sep 2023 |
Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer
|
|
22 Sep 2023 |
Merck Announces Phase 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
|
|
22 Sep 2023 |
Meitheal Announces Exclusive Commercial Licensing Agreement for Insulin Biosimilars in the U.S.
|
|
22 Sep 2023 |
SELLAS Announces Positive Topline Data in Lymphoma Cohort from SLS009 Phase 1 Dose-Escalation Trial, Supporting Advancement to Phase 2 Clinical Study; Primary and Secondary Endpoints Met
|
|
22 Sep 2023 |
Krystal Biotech Announces FDA Clearance of Investigational New Drug Application for KB408 for the Treatment of Type 1 Alpha-1 Antitrypsin Deficiency
|
|
22 Sep 2023 |
Inmagene announces formation of Celexor Bio based on its anti-ILT7 mAb with enhanced pDC depletion function
|
|
22 Sep 2023 |
Via Nova Therapeutics Announces FDA clearance of Investigational New Drug (IND) application for VNT-101, a novel direct-acting antiviral against Influenza A virus
|
|
22 Sep 2023 |
Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
|
|
22 Sep 2023 |
Datopotamab Deruxtecan Demonstrated Statistically Significant and Clinically Meaningful Progression-Free Survival Benefit in Patients with HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial
|
|
21 Sep 2023 |
Antengene Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031
|
|
21 Sep 2023 |
Leucid Bio Granted MHRA Clinical Trial Authorisation for Lateral NKG2D CAR-T Cell Therapy LEU011
|
|
21 Sep 2023 |
Fresenius Kabi’s biosimilar Tyenne®* becomes first tocilizumab biosimilar approved by the European Commission
|
|
21 Sep 2023 |
Debiopharm and SunRock Biopharma Partner to Advance Antibody Drug Conjugates for Hard-to-treat Cancers
|
|
20 Sep 2023 |
Alvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira® (adalimumab)
|
|
20 Sep 2023 |
Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV
|
